Molecular signatures of ovarian cancer
Described herein are gene signatures providing prognostic, diagnostic, treatment and molecular subtype classifications of ovarian cancers through generation of ovarian cancer disease signatures (OCDSs) that account for molecular heterogeneity present in gynecological cancers. An ovarian cancer fixed signature (OCFS) is described which relates to the core programming of disease development, in addition to an ovarian cancer stem cell (OCSC) signature. Development various disease signature, suggests personalized treatment strategies focused on molecular subtypes of gynecological cancers, such as triage tests for patients.
1. A method of determining the presence or absence of a high level of expression of 10 genes in a human individual with serous ovarian cancer, comprising:
obtaining a biological sample from the human individual with serous ovarian cancer, and
detecting the presence or absence of a high level of expression in the human individual with serous ovarian cancer, relative to a normal baseline standard from human individuals, for 10 genes wherein the 10 genes consist of AEBP1, COL11A1, COL5A1, COL6A2, LOX, POSTN, SNAI2, THBS2, TIMP3, and VCAN, and wherein the detecting comprises measuring the expression level of the 10 genes using quantitative real-time PCR.
2. The method of claim 1 , further comprising administering treatment to the individual with serous ovarian cancer.
3. The method of claim 2 , wherein the treatment comprises primary debulking surgery (PDS) followed by chemotherapy and/or neoadjuvant chemotherapy followed by interval cytoreduction.
4. The method of claim 3 , wherein chemotherapy is selected from the group consisting of paclitaxel, cisplatin, carboplatin and combinations thereof.
5. The method of claim 1 , wherein the biological sample comprises ovarian cyst fluid, urine, or serum.
6. The method of claim 1 , wherein the biological sample comprises a tumor biopsy sample.